UNSPSC 51162300: Combination cold remedies

This classification denotes combination drugs and preparations that alleviate symptons of and treat a catarrhal disorder of the upper respiratory tract, which may be viral or a mixed infection. It generally involves a runny nose, nasal congestion, and sneezing, called the Common Cold, hence the term COLD REMEDIES.

Typical combination cold remedy constituents are acetaminophen, ammonium, ammonium chloride, aspirin, atropine, belladonna, benzocaine, caffeine, calcium lactate, caramiphen, chlorpheniramine, citric, diphenhydramine, ibuprofen, magnesium salicylate, methscopolamine, naproxen, and potassium guaiacolsulfonate.

UNSPSC 51162300 Combination cold remedies, a Class code, nominally encompasses pharmaceutical products; however, recent state and local activity under this code focuses on naloxone and safe drug deactivation systems for harm-reduction and emergency response, rather than traditional cold or cough remedies. State and local buyers soliciting under this code include county health departments and multistate cooperative purchasing alliances administering centralized pharmaceutical procurement for distributed networks of public facilities. Seminole County, Florida, for example, procures naloxone and drug deactivation systems through competitive bidding to support community health initiatives with quarterly deliveries to county health facilities. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, solicits manufacturers of generic pharmaceuticals and OTC products through centralized RFPs designed to serve participating state and local government facilities across multiple states, including Oregon. The mismatch between the code's nominal scope and actual recent procurement suggests this code may be applied inconsistently by issuing bodies or may reflect changes in harm-reduction procurement taxonomy within the state and local sector.

Recent opportunities posted in June 2026 and January 2026 show activity concentrated in Florida and the MMCAP multistate network centered in Minnesota. Seminole County issued IFB60459723LAS on June 30, 2026, requesting 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023 (note: date discrepancy in source), with quarterly deliveries to the Seminole County Community Health Building and shipping included in vendor pricing. The Minnesota Department of Administration issued RFP S1070000015802 on January 20, 2026, with a response deadline of March 26, 2026, establishing multiple contracts for generic pharmaceuticals and OTC products through authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson) with awards effective July 1, 2026. Both solicitations require vendor compliance with federal drug-supply regulations, cGMP certification, insurance coverage, and E-Verify eligibility; neither identifies explicit set-aside designations for disadvantaged enterprises based on available documentation.